Abstract
Impaired function of the phospholamban (PLB)-regulated sarcoplasmic reticulum Ca2+ pump (SERCA2a) contributes to cardiac dysfunction in heart failure (HF). PLB downregulation may increase SERCA2a activity and improve cardiac function. Small interfering (si)RNAs mediate efficient gene silencing by RNA interference (RNAi). However, their use for in vivo gene therapy is limited by siRNA instability in plasma and tissues, and by low siRNA transfer rates into target cells. To address these problems, we developed an adenoviral vector (AdV) transcribing short hairpin (sh)RNAs against rat PLB and evaluated its potential to silence the PLB gene and to modulate SERCA2a-mediated Ca2+ sequestration in primary neonatal rat cardiomyocytes (PNCMs). Over a period of 13 days, vector transduction resulted in stable >99.9% ablation of PLB-mRNA at a multiplicity of infection of 100. PLB protein gradually decreased until day 7 (7±2% left), whereas SERCA, Na+/Ca2+ exchanger (NCX1), calsequestrin and troponin I protein remained unchanged. PLB silencing was associated with a marked increase in ATP-dependent oxalate-supported Ca2+ uptake at 0.34 μ M of free Ca2+, and rapid loss of responsiveness to protein kinase A-dependent stimulation of Ca2+ uptake was maintained until day 7. In summary, these results indicate that AdV-derived PLB-shRNA mediates highly efficient, specific and stable PLB gene silencing and modulation of active Ca2+ sequestration in PNCMs. The availability of the new vector now enables employment of RNAi for the treatment of HF in vivo.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- AdV:
-
adenovector
- AdV:
-
adenoviral vector
- PLB:
-
phospholamban
- PNCM:
-
primary neonatal rat cardiomyocytes
- RNAi:
-
RNA interference
- SERCA2a:
-
sarcoplasmic reticulum Ca2+ pump
- shRNA:
-
short hairpin RNA
- siRNA:
-
small interfering RNA
References
Piacentino III V, Weber CR, Chen X, Weisser-Thomas J, Margulies KB, Bers DM et al. Cellular basis of abnormal calcium transients of failing human ventricular myocytes. Circ Res 2003; 92: 651–658.
Wolska BM, Arteaga GM, Pena JR, Nowak G, Phillips RM, Sahai S et al. Expression of slow skeletal troponin I in hearts of phospholamban knockout mice alters the relaxant effect of beta-adrenergic stimulation. Circ Res 2002; 90: 882–888.
Schmidt U, Hajjar RJ, Kim CS, Lebeche D, Doye AA, Gwathmey JK . Human heart failure: cAMP stimulation of SR Ca2+-ATPase activity and phosphorylation level of phospholamban. Am J Physiol 1999; 277: H474–H480.
Luo W, Grupp IL, Harrer J, Ponniah S, Grupp G, Duffy JJ et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res 1994; 75: 401–409.
Iwanaga Y, Hoshijima M, Gu Y, Iwatate M, Dieterle T, Ikeda Y et al. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest 2004; 113: 727–736.
Hoshijima M, Ikeda Y, Iwanaga Y, Minamisawa S, Date MO, Gu Y et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 2002; 8: 864–871.
Eizema K, Fechner H, Bezstarosti K, Schneider-Rasp S, van der Laarse A, Wang H et al. Adenovirus-based phospholamban antisense expression as a novel approach to improve cardiac contractile dysfunction: comparison of a constitutive viral versus an endothelin-1-responsive cardiac promoter. Circulation 2000; 101: 2193–2199.
Li J, Hu SJ, Sun J, Zhu ZH, Zheng X, Wang GZ et al. Construction of phospholamban antisense RNA recombinant adeno-associated virus vector and its effects in rat cardiomyocytes. Acta Pharmacol Sin 2005; 26: 51–55.
He H, Meyer M, Martin JL, McDonough PM, Ho P, Lou X et al. Effects of mutant and antisense RNA of phospholamban on SR Ca2+-ATPase activity and cardiac myocyte contractility. Circulation 1999; 100: 974–980.
del Monte F, Harding SE, Dec GW, Gwathmey JK, Hajjar RJ . Targeting phospholamban by gene transfer in human heart failure. Circulation 2002; 105: 904–907.
Dieterle T, Meyer M, Gu Y, Belke DD, Swanson E, Iwatate M et al. Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure. Cardiovasc Res 2005; 67: 678–688.
Meyer M, Belke DD, Trost SU, Swanson E, Dieterle T, Scott B et al. A recombinant antibody increases cardiac contractility by mimicking phospholamban phosphorylation. FASEB J 2004; 18: 1312–1314.
Watanabe A, Arai M, Yamazaki M, Koitabashi N, Wuytack F, Kurabayashi M . Phospholamban ablation by RNA interference increases Ca2+ uptake into rat cardiac myocyte sarcoplasmic reticulum. J Mol Cell Cardiol 2004; 37: 691–698.
Leung RK, Whittaker PA . RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther 2005; 107: 222–239.
Ogorelkova M, Zwaagstra J, Elahi SM, Dias C, Guilbaut C, Lo R et al. Adenovirus-delivered antisense RNA and shRNA exhibit different silencing efficiencies for the endogenous transforming growth factor-beta (TGF-beta) type II receptor. Oligonucleotides 2006; 16: 2–14.
Lewis DL, Hagstrom JE, Loomis AG, Wolff JA, Herweijer H . Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet 2002; 32: 107–108.
Odermatt A, Kurzydlowski K, MacLennan DH . The vmax of the Ca2+-ATPase of cardiac sarcoplasmic reticulum (SERCA2a) is not altered by Ca2+/calmodulin-dependent phosphorylation or by interaction with phospholamban. J Biol Chem 1996; 271: 14206–14213.
Hajjar RJ, Schmidt U, Matsui T, Guerrero JL, Lee KH, Gwathmey JK et al. Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci USA 1998; 95: 5251–5256.
del Monte F, Williams E, Lebeche D, Schmidt U, Rosenzweig A, Gwathmey JK et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca2+-ATPase in a rat model of heart failure. Circulation 2001; 104: 1424–1429.
Vetter R, Rehfeld U, Reissfelder C, Weiss W, Wagner KD, Gunther J et al. Transgenic overexpression of the sarcoplasmic reticulum Ca2+ATPase improves reticular Ca2+ handling in normal and diabetic rat hearts. FASEB J 2002; 16: 1657–1659.
Miyamoto MI, del Monte F, Schmidt U, DiSalvo TS, Kang ZB, Matsui T et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA 2000; 97: 793–798.
Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005; 23: 321–328.
Muller OJ, Leuchs B, Pleger ST, Grimm D, Franz WM, Katus HA et al. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res 2006; 70: 70–78.
Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, Miller DG et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 2004; 10: 828–834.
Kawamoto S, Shi Q, Nitta Y, Miyazaki J, Allen MD . Widespread and early myocardial gene expression by adeno-associated virus vector type 6 with a beta-actin hybrid promoter. Mol Ther 2005; 11: 980–985.
Inagaki K, Fuess S, Storm TA, Gibson GA, McTiernan CF, Kay MA et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006; 14: 45–53.
Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005; 23: 321–328.
Schmitt JP, Kamisago M, Asahi M, Li GH, Ahmad F, Mende U et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 2003; 299: 1410–1413.
Haghighi K, Kolokathis F, Pater L, Lynch RA, Asahi M, Gramolini AO et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest 2003; 111: 869–876.
Zhao W, Yuan Q, Qian J, Waggoner JR, Pathak A, Chu G et al. The presence of Lys27 instead of Asn27 in human phospholamban promotes sarcoplasmic reticulum Ca2+-ATPase superinhibition and cardiac remodeling. Circulation 2006; 113: 995–1004.
Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, Gu Y et al. Chronic phospholamban–sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 1999; 99: 313–322.
Vetter R, Kott M, Schulze W, Rupp H . Influence of different culture conditions on sarcoplasmic reticular calcium transport in isolated neonatal rat cardiomyocytes. Mol Cell Biochem 1998; 188: 177–185.
Sipo I, Wang X, Hurtado PA, Suckau L, Weger S, Poller W et al. Tamoxifen-regulated adenoviral E1A chimeras for the control of tumor selective oncolytic adenovirus replication in vitro and in vivo. Gene Therapy 2006; 13: 173–186.
Marienfeld U, Haack A, Thalheimer P, Schneider-Rasp S, Brackmann HH, Poller W . ‘Autoreplication’ of the vector genome in recombinant adenoviral vectors with different E region deletions and transgenes. Gene Therapy 1999; 6: 1101–1113.
Fechner H, Wang X, Wang H, Jansen A, Pauschinger M, Scherubl H et al. Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells. Gene Therapy 2000; 7: 1954–1968.
Fechner H, Haack A, Wang H, Wang X, Eizema K, Pauschinger M et al. Expression of Coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Therapy 1999; 6: 1520–1535.
Cernohorsky J, Kolar F, Pelouch V, Korecky B, Vetter R . Thyroid control of sarcolemmal Na+/Ca2+ exchanger and SR Ca2+-ATPase in developing rat heart. Am J Physiol 1998; 275: H264–H273.
Acknowledgements
This work was supported by the Deutsche Forschungsgemeinschaft through a research grant to WP, and through the SFB Transregio 19.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fechner, H., Suckau, L., Kurreck, J. et al. Highly efficient and specific modulation of cardiac calcium homeostasis by adenovector-derived short hairpin RNA targeting phospholamban. Gene Ther 14, 211–218 (2007). https://doi.org/10.1038/sj.gt.3302872
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302872
Keywords
This article is cited by
-
Phospholamban phosphorylation, mutation, and structural dynamics: a biophysical approach to understanding and treating cardiomyopathy
Biophysical Reviews (2015)
-
microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors
Gene Therapy (2011)
-
Antisense Makes Sense in Engineered Regenerative Medicine
Pharmaceutical Research (2009)
-
Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy
Journal of Molecular Medicine (2008)
-
Coxsackievirus B3 and adenovirus infections of cardiac cells are efficiently inhibited by vector-mediated RNA interference targeting their common receptor
Gene Therapy (2007)